UNSPSC 51363502: Aprobarbital/butabarbital/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN301. This VA Drug Class (CN301) classifies this compound as belonging to the group BARBITURIC ACID DERIVATIVE SEDATIVES/HYPNOTICS.

UNSPSC 51363502 Aprobarbital/butabarbital/phenobarbital is a Commodity code covering controlled and non-controlled barbiturate pharmaceuticals; state and local governments purchase these products primarily through pharmacy benefit programs, cooperative purchasing agreements, and direct procurement for public health initiatives. Recent solicitations show demand spanning community health naloxone acquisition, statewide generic pharmaceutical contracting, and exploratory direct-to-manufacturer pharmacy programs. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both direct health-department procurement and larger statewide frameworks that aggregate demand across participating government entities.

Recent activity concentrates in Florida and Texas, with multistate cooperative procurement centered in Minnesota. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries with fixed-fee pricing and federal compliance requirements tied to potential FEMA funding. The Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) exploring direct-to-manufacturer prescription programs to improve fulfillment efficiency and negotiate net pricing outside traditional PBM and GPO channels. MMCAP's RFP (S1070000015802, due March 26, 2026) established multistate contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with pricing weighted at 75 percent and all products required to achieve marketplace availability by May 15, 2026, with an effective date of July 1, 2026. Vendors must meet cGMP and Drug Supply Chain Security Act certification, maintain relationships with at least two of three designated wholesalers, and carry insurance including commercial general liability of $5 million per occurrence.